Division of Urologic Surgery, Department of Surgery, and Duke Prostate Center, Duke University School of Medicine, Durham, NC 27710, USA.
Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):9-17. doi: 10.1158/1055-9965.EPI-09-0777.
Diabetes is associated with lower prostate cancer risk. The association of diabetes with prostate cancer outcomes is less clear. We examined the association between diabetes and outcomes after radical prostatectomy and tested whether associations varied by race and/or obesity.
This study is a retrospective analysis of 1,262 men treated with radical prostatectomy between 1988 and 2008 within the Shared Equal-Access Regional Cancer Hospital database. We examined the multivariate association between diabetes at surgery and adverse pathology, biochemical recurrence (BCR), and prostate-specific antigen doubling time at recurrence using logistic, proportional hazards, and linear regression, respectively. Data were examined as a whole and stratified by race and obesity.
Diabetes was more prevalent among black (22% versus 15%, P < 0.001) and more obese men (P < 0.001). Diabetes was associated with higher tumor grade (odds ratio, 1.73; P = 0.002), seminal vesicle invasion (odds ratio, 1.73; P = 0.04), but not BCR (P = 0.67) or PSADT at recurrence (P = 0.12). In the secondary analysis, among white obese men, diabetes was associated with 2.5-fold increased BCR risk (P = 0.002) and a trend toward shorter PSADT, whereas among all other men (nonobese white men and black men), diabetes was associated with 23% lower recurrence risk (P = 0.09) and longer PSADT (P = 0.04).
In a radical prostatectomy cohort, diabetes was not associated with BCR. In the secondary analysis, diabetes was associated with more aggressive disease in obese white men and less aggressive disease for all other subsets. If externally validated, these findings suggest that among men with prostate cancer, the association between diabetes and prostate cancer aggressiveness may vary by race and obesity.
糖尿病与前列腺癌风险降低有关。糖尿病与前列腺癌结局之间的关联尚不清楚。我们研究了糖尿病与根治性前列腺切除术治疗后结局之间的关系,并检验了这种关联是否因种族和/或肥胖而有所不同。
本研究为回顾性分析,纳入了 1988 年至 2008 年间在共享平等准入区域癌症医院数据库中接受根治性前列腺切除术治疗的 1262 名男性患者。我们分别使用逻辑回归、比例风险回归和线性回归分析了手术时糖尿病与不良病理学、生化复发(BCR)和复发时前列腺特异性抗原倍增时间之间的多变量关联。数据作为整体进行了检验,并按种族和肥胖程度进行了分层。
黑人(22%比 15%,P < 0.001)和肥胖男性中糖尿病更为常见(P < 0.001)。糖尿病与肿瘤分级更高(优势比,1.73;P = 0.002)、精囊侵犯(优势比,1.73;P = 0.04)相关,但与 BCR 无关(P = 0.67)或复发时 PSA 倍增时间无关(P = 0.12)。在次要分析中,在白人肥胖男性中,糖尿病与 BCR 风险增加 2.5 倍相关(P = 0.002),且 PSA 倍增时间有缩短趋势,而在所有其他男性(非肥胖白人男性和黑人男性)中,糖尿病与复发风险降低 23%相关(P = 0.09),且 PSA 倍增时间延长(P = 0.04)。
在根治性前列腺切除术队列中,糖尿病与 BCR 无关。在次要分析中,糖尿病与肥胖白人男性中更具侵袭性的疾病相关,而与所有其他亚组中侵袭性较低的疾病相关。如果外部验证成立,这些发现表明,在患有前列腺癌的男性中,糖尿病与前列腺癌侵袭性之间的关联可能因种族和肥胖程度而异。